ArticleKidney international2021

Kidney toxicity of the BRAF-kinase inhibitor vemurafenib is driven by off-target ferrochelatase inhibition.

Yuntao Bai et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.